Clinical Oncology
Volume 19, Issue 2 , Pages 135-142 , March 2007

Challenges in Treating Patients with Down's Syndrome and Testicular Cancer with Chemotherapy and Radiotherapy: The Royal Marsden Experience

  • S. Hafeez

      Affiliations

    • Radiotherapy Department, Royal Marsden Hospital NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    • ,
  • R.A. Sharma

      Affiliations

    • Radiotherapy Department, Royal Marsden Hospital NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    • Radiation Oncology and Biology, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    • Corresponding Author InformationAuthor for correspondence: R. A. Sharma, Radiation Oncology and Biology, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK. Tel: +44-208-642-6011.
    • ,
  • R.A. Huddart

      Affiliations

    • Radiotherapy Department, Royal Marsden Hospital NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    • ,
  • D.P. Dearnaley

      Affiliations

    • Radiotherapy Department, Royal Marsden Hospital NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    • ,
  • A. Horwich

      Affiliations

    • Radiotherapy Department, Royal Marsden Hospital NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK

Received 7 September 2006 ,Revised 29 September 2006 ,Accepted 20 October 2006.

References 

  1. In:  McIntosh N,  Helms PJ,  Smyth RL editor. Forfar and Arneil's textbook of pediatrics. 6th edn. New York: Churchill Livingstone; 2003;
  2. Penrose LS. The incidence of Mongolism in the general population. J Ment Sci. 1949;95:685–688
  3. Eyman RK, Call TL, White JF. Life expectancy of persons with Down's syndrome. Am J Ment Retard. 1991;95:603–612
  4. Bittles AH, Glasson EJ. Clinical, social and ethical implications of changing life expectancy in Down syndrome. Dev Med Child Neurol. 2004;46:282–286
  5. Day SM, Strauss DJ, Shavelle RM, Reynolds RJ. Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol. 2005;47:171–176
  6. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol. 2001;2:429–436
  7. Satage D, Sasco AJ, Cure H, Leduc B, Sommelet D, Vekemans MJ. An excess of testicular germ cell tumours in Down's syndrome: three case reports and a review of the literature. Cancer. 1997;80:929–935
  8. Dexeus FH, Logothetis CJ, Chong C, Sella A, Ogden S. Genetic abnormalities in men with germ cell tumours. J Urol. 1988;140:80–84
  9. Diekermann KP, Rube C, Henke RP. Association of Down's syndrome and testicular cancer. J Urol. 1997;157:1701–1704
  10. Benson RC, Beard CM, Kelalis PP, Kurland LT. Malignant potential of the cryptoorchid testis. Mayo Clin Proc. 1991;66:372–378
  11. Smucker JD, Roth LM, Sutton GP, Hurteau JA. Trisomy 21 associated with ovarian dysgerminoma. Gynecol Oncol. 1999;74:512–514
  12. Cools M, Honecker F, Stoop FH, et al. Maturation delay of germ cell in fetuses with trisomy 21 results in increased risk for the development of testicular germ cell tumours. Human Pathol. 2006;37:101–111
  13. Forman D, Pike MC, Davey G, et al. Aetiology of testicular cancer; association with congenital abnormalities, age at puberty, infertility and exercise. Br Med J. 1994;308:1393–1399
  14. Meyts RE, Skakkebaek NE. The possible role of sex hormones in the development of testicular cancer. Eur Urol. 1993;23:54–61
  15. Horwich A, Malcom DM, Hendry WF. Testicular tumours. In:  Peckham M,  Pinedo H,  Yeronesi U editor. Oxford textbook of oncology. Vol. 2:Oxford: Oxford University Press; 1995;p. 1407–1414
  16. Roberge D, Souhami L, Laplante M. Testicular seminoma and Down's syndrome. Can J Urol. 2001;8:1203–1206
  17. Gibson D. Down's syndrome: the psychology of Mongolism. Cambridge: Cambridge University Press; 1978;
  18. Myers BA, Pueschel SM. Psychiatric disorders in a population with Down's syndrome. J Nerv Ment Dis. 1991;179:609–613
  19. Hasen J, Boyar RM, Shapiro LR. Gonadal function in trisomy 21. Horm Res. 1980;12:345–350
  20. Sasagawa I. Hormone profiles and contralateral testicular histology in Down's syndrome with unilateral testicular tumor. Arch Androl. 1993;30:93–98
  21. Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organization for the Research and Treatment of Cancer trial 30942. J Clin Oncol. 2005;23:1200–1208
  22. Oliver RTD, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet. 2005;366:293–300
  23. Horwich A, Shipley J, Huddart R. Testicular germ cell cancer. Lancet. 2006;367:754–765
  24. Vallis KA, Horward GC, Duncan W, et al. Radiotherapy for stages I and II testicular seminoma; results and morbidity in 238 patients. Br J Radiol. 1995;68:400–405
  25. Warde P, Gospodarowicz M, Panzarella T, et al. Management of stage II seminoma. J Clin Oncol. 1998;16:290–294
  26. Zagars GK, Pollack A. Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys. 2001;51:643–649
  27. Patterson H, Norman AR, Mitra SS, et al. Combination of carboplatin and radiotherapy in the management of stage II testicular seminoma; comparison with radiotherapy treatment alone. Radiother Oncol. 2001;59:5–11
  28. Chung PW, Gospodorwicz MK, Panzarella T, et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol. 2004;45:754–760
  29. Roizen NJ, Patterson D. Down's syndrome. Lancet. 2003;361:1281–1298
  30. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000;110:512–524

PII: S0936-6555(06)00407-9

doi: 10.1016/j.clon.2006.10.006

Clinical Oncology
Volume 19, Issue 2 , Pages 135-142 , March 2007

Article Tools